What is Endologix's stock symbol?
Endologix trades on the NASDAQ under the ticker symbol "ELGX."
Where is Endologix's stock going? Where will Endologix's stock price be in 2017?
10 equities research analysts have issued twelve-month target prices for Endologix's stock. Their predictions range from $6.30 to $16.00. On average, they expect Endologix's share price to reach $10.38 in the next twelve months.
When will Endologix announce their earnings?
Endologix is scheduled to release their next quarterly earnings announcement on Monday, May, 8th 2017.
What are analysts saying about Endologix stock?
Here are some recent quotes from research analysts about Endologix stock:
According to Zacks Investment Research, "Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. " (1/23/2017)
Canaccord Genuity analysts commented, "We note the company’s next-gen AFX2 system incorporates design improvements as well as an updated IFU to decrease the occurrence of Type III endoleaks (zero Type III endoleaks have been reported with AFX2 platform in Europe)." (12/13/2016)
Who owns Endologix stock?
Endologix's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Arrowpoint Asset Management LLC (7.85%), Columbia Wanger Asset Management LLC (7.64%), Brown Capital Management LLC (7.39%), FMR LLC (2.96%), Janus Capital Management LLC (2.13%) and State Street Corp (1.89%). Company insiders that own Endologix stock include Amanda L Depalma, Charles Steele Love, Gregory D Waller, Guido J Neels, James Edward Machek, John D Mcdermott, Jose A Lima, Joseph A Dejohn, Michael V Chobotov, Robert D Mitchell, Thomas F Zenty III, Thomas Wilder, Todd Abraham and Vaseem Mahboob.
Who sold Endologix stock? Who is selling Endologix stock?
Endologix's stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, GRT Capital Partners L.L.C., NN Investment Partners Holdings N.V. and Metropolitan Life Insurance Co. NY. Company insiders that have sold Endologix stock in the last year include Amanda L Depalma, Gregory D Waller, James Edward Machek, John D Mcdermott, Jose A Lima, Joseph A Dejohn, Michael V Chobotov and Robert D Mitchell.
Who bought Endologix stock? Who is buying Endologix stock?
Endologix's stock was purchased by a variety of institutional investors in the last quarter, including Columbia Wanger Asset Management LLC, Brown Capital Management LLC, Arrowpoint Asset Management LLC, Broadfin Capital LLC, FMR LLC, Marshall Wace LLP, State Street Corp and Two Sigma Investments LP. Company insiders that have bought Endologix stock in the last two years include Guido J Neels, John D Mcdermott, Thomas F Zenty III, Todd Abraham and Vaseem Mahboob.
How do I buy Endologix stock?
Shares of Endologix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Endologix stock cost?
One share of Endologix stock can currently be purchased for approximately $6.28.